◎Penetration of methotrexate into the cerebrospinal fluids after the high dose infusion in patients with malignant lymphoma. Suzuki Y., Itoh H., Nishimura F., Abe T., Sato Y., Takeyama M. 70th International Congress of FIP (Lisbon, Portugal) 2010.8

◎Effect of Goshajinkigan, a Japanese traditional medicine, on plasma levels of calcitonin gene-related peptide, vasoactive intestinal polypeptide, and substance P in humans　 Arao K., Sato Y., Suzuki Y., Abe T., Itoh, H. Takeyama M.,　The 23rd Federation of Asian Pharmaceutical Associations Congress(Taipei, Taiwan) 2010.11

◎Effect of cevimeline on salivary neuropeptide levels in healthy volunteers. Suzuki Y., Itoh H., Nishimura F., Abe T., Sato Y., Takeyama M. 5th International Peptide Symposium in conjuction with 47th Japanese Peptide Symposium (Kyoto, Japan) 2010.12

◎Pantethine Raises Plasma Levels of Calcitonin Gene-related Peptide and Vasoactive Intestinal Polypeptide in Healthy Volunteers Suzuki Y., Itoh H., Nishimura F., Tatsuta R., Sato Y., Takeyama M. 10th Congress of the European Association for Clinical Pharmacology and Therapeutics (Budapest, Hungary) 2011.6

◎Therapeutic Drug Monitoring of Individual Teicoplanin Components; Factors Affecting Pharmacokinetics of Individual Teicoplanin Components. Suzuki Y., Itoh H., Kawasaki K., Sato Y., Takeyama M. 12th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology (Stuttgart, Germany) 2011.10

◎Mirtazapine Suppresses the Increases in Plasma Levels of Adrenocorticotropic Hormone and Neuropeptide Y under Continual Stress Exposure　Arao K., Makihara Y., Suzuki Y., Abe T., Sato Y., Takeyama M. 2012 American Society for Clinical Pharmacology and Therapeutics Annual Meeting (Maryland, America) 2012.3

◎Significant Increase in Plasma 4β-Hydroxycholesterol Concentration as an Endogenous Marker of CYP3A Activity in Patients with End-Stage Renal Disease after Kidney Transplantation. Suzuki Y., Itoh H., Sato F., Kawasaki K., Sato Y., Fujioka T., Sato Y., Ohno K., Mimata H., Kishino S., 13th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology (Salt Lake, USA) 2013.9

◎A Retrospective Analysis to Estimate Target Trough Concentration of Vancomycin for Febrile Neutropenia in Patients with Hematological Malignancy.Suzuki Y., Tokimatsu I., Morinaga Y., Sato Y., Hashinaga K., Takano K., Kohno K., Ogata M., Hiramatsu K., Itoh H., Kadota JI.,54th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington DC, USA) 2014.9

◎A Individual difference in metabolic capacity by CYP3A5 genetic polymorphism affects cross-reactivity in various tacrolimus assays. Kaneko T, Fujioka T, Suzuki Y, Nagano T, Sato F, Sato Y, Asakura S, Mimata H, Itoh H.,19th North American Regional ISSX / 29th ISSX Annual Meeting (San Francisco, USA) 2014.10

◎Characterization of the structure of human serum albumin in patients with end stage renal disease after kidney transplantation. Tanaka R, Suzuki Y, Imafuku T, Sato F, Ishima Y, Sato Y, Watanabe H, Maruyama T, Mimata H, Itoh H., The 12th Congress of the European Association for Clinical Pharmacology and Therapeutics. (Madrid, Spain) 2015.6

◎CYP3A5 Polymorphism Affects the Increase in CYP3A Activity after Living Kidney Transplantation in Patients with End Stage Renal Disease. Suzuki Y., Fujioka T., Sato F., Matsumoto K., Muraya N., Tanaka R., Sato Y., Ohno K., Mimata H., Kishino S. Itoh H. The 12th Congress of the European Association for Clinical Pharmacology and Therapeutics (Madrid, Spain) 2015.6

◎Development of simultaneous quantification of free itraconazole and hydroxy itraconazole in human plasma using ultra performance liquid chromatography-tandem mass spectrometry. Oyama N, Suzuki Y, Fujioka T,Kaneko T,Tanaka R, Sato Y,Itoh H 75th FIP World Congress of Pharmacy and Pharmaceutical Sciences 2015 (FIP) (Dusseldorf , Germany) 2015.9　　　　

◎CYP3A5 polymorphism and accumulation of indoxyl sulfate affect the rate of increase in CYP3A activity after living kidney transplantation in patients with end stage renal disease.Suzuki Y., Fujioka T., Muraya N., Sato F., Matsumoto K., Tanaka R., Sato Y., Ohno K., Mimata H., Kishino S. Itoh H.14th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology (Rotterdam, the Netherlands) 2015.10

◎Establishment of simultaneous quantification of estrone and 16α-hydroxyestrone in human urine using ultra performance liquid chromatography-tandem mass spectrometry. Tetsuya Kaneko, Yosuke Suzuki, Takashi Fujioka, Ryota Tanaka, Nobuhiro Oyama, Yuhki Sato, Hiroki Itoh. 14th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology (Rotterdam, The Netherlands) 2015.10

◎Therapeutic strategy with Japanese Kampo medicine for gastrointestinal disease based on the gut-regulated peptide levels in human body fluid. Sato Y, Suzuki Y, Tanaka R, Iwao M, Kaneko T, Itoh H., BIT's 9th Annual World Protein＆Peptide Conference-2016. (Dailian, China) 2016.4

◎Determination of nilotinib with high-performance liquid chromatography in human plasma from patients with chronic myelogenous leukemia, and its applications.. Nakahara R, Sumimoto T, Sato Y, Itoh H, 45th ESCP Annual Symposium Clinical pharmacy tackling inequalities and access to health care. (Oslo, Norway) 2016.10

◎Monte Carlo simulation of doripenem in patients admitted to intensive care unit. Tanaka R,Sato Y,Suzuki Y,Goto K,Yasuda N,Ohchi Y,Ueno T,Kaneko T,Nonoshita K,Itoh H., The 13th European Association for Clinical Pharmacology & Therapeutics Congress (Czech Republic, Prague) 2017.6

◎Clinical evaluation of the crude drugs with gastrointestinal peptide in human body fluid (Invited Speaker). Sato Y, Itoh H., 77th FIP World Congress of Pharmacy and Pharmaceutical Sciences (Seul, Korea) 2017.9

◎Ultra-sensitive quantification of drugs and endogenous substances in human plasma using UPLC-MS/MS. (Invited Speaker). Suzuki Y., 15th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology (Kyoto, Japan) 2017.9

◎Phenoconversion of CYP3A in chronic renal failure; what is the factor involved?. Suzuki Y, Muraya N, Fujioka T, Sato F, Tanaka R, Matsumoto K, Sato Y, Ohno K, Mimanta H, Kishino S, Itoh H., 15th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology (Kyoto, Japan) 2017.9

◎Simultaneous quantification of 5-FU, uracil and tegafur using ultra-performance liquid chromatography coupled to tandem mass spectrometry Shiraiwa K, Suzuki Y, Iwao M, Kaneko T, Sato Y, Iwashita Y,Uchida H, Tada K, Inomata M,Itoh H.,15th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology (Kyoto, Japan) 2017.9

◎Quantification of pazopanib in plasma of patients with soft tissue tumors using ultra-performance liquid chromatography coupled to tandem mass spectrometry. Shiraiwa K, Suzuki Y, Tanaka K, Kawano M, Iwasaki T, Tanaka R, Sato Y, Tsumura H, Itoh H, 16th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology (Brisbane、Australia) 2018.9

◎Sensitive and high-throughput UPLC-MS/MS method for simultaneous quantification of imatinib, N-desmethyl-imatinib, nilotinib, dasatinib, bosutinib, ponatinib and N-desmethyl-ponatinib in human plasma. Sumimoto T, Nakahara R, Suzuki Y, Sato Y, Ogata M, Itoh H, 16th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology (Brisbane, Australia) 2018.9

◎Relationship between digestive function abnormality and blood levels of gastrointestinal peptides in patients receiving anticancer agents combined with aprepitant. Tatsuta R, Suzuki Y, Suzuki K, Sato Y, Shibata T, Itoh H, THE 14th Congress of the European Association for Clinical Pharmacology and Therapeutics (Stockholm, Sweden) 2019.6

◎Simultaneous quantification of plasma levels of 12 antimicrobial agents used in intensive care unit using UPLC-MS/MS method. Kai M, Tanaka R, Suzuki Y, Goto K, Ohchi Y, Koga H, Yasuda N, Sato Y, Kitano T, Itoh H. The 17th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology (Foz do Iguassu, Brazil) 2019.9

◎Significant decrease in plasma concentrations of coproporphyrin-I, a specific endogenous OATP1B probe, after living kidney transplantation in patients with end-stage renal disease. Suzuki Y, Ono H, Tanaka R, Sato F, Sato Y, Ohno K, Mimata H, Itoh H. The 17th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology (Foz do Iguassu, Brazil) 2019.9